SYMQY (SymBio Pharmaceuticals) Scaled Net Operating Assets: 0.08 (As of Dec. 2025)


SYMQY SymBio Pharmaceuticals Ltd SYMQY
35 GF Score
Price $0.56
GF Value $0.44
! 6 Warning Signs
View Full Analysis

What is SymBio Pharmaceuticals Scaled Net Operating Assets?

SymBio Pharmaceuticals SYMQY -12.42% 35 Scaled Net Operating Assets is 0.08 as of Dec. 2025. GuruFocus rates SYMQY with a GF Score™ of 35/100 and a GF Value™ of $0.44. The stock has 6 warning signs investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

SymBio Pharmaceuticals's operating assets for the quarter that ended in Dec. 2025 was $6.31 Mil. SymBio Pharmaceuticals's operating liabilities for the quarter that ended in Dec. 2025 was $3.93 Mil. SymBio Pharmaceuticals's Total Assets for the quarter that ended in Sep. 2025 was $30.98 Mil. Therefore, SymBio Pharmaceuticals's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2025 was 0.08.

SymBio Pharmaceuticals Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for SymBio Pharmaceuticals's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SymBio Pharmaceuticals Scaled Net Operating Assets Chart

SymBio Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.42 0.22 0.06 0.03 0.07

SymBio Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 0.14 0.13 0.08 -0.16

SYMQY vs ZTS, UTHR: Scaled Net Operating Assets Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, SymBio Pharmaceuticals's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SymBio Pharmaceuticals Scaled Net Operating Assets vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SymBio Pharmaceuticals's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where SymBio Pharmaceuticals's Scaled Net Operating Assets falls into.


SYMQY
35GF Score
SymBio Pharmaceuticals Ltd SYMQY
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SymBio Pharmaceuticals Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

SymBio Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2025 )
=(Operating Assets (A: Dec. 2025 )-Operating Liabilities (A: Dec. 2025 ))/Total Assets (A: Dec. 2024 )
=(6.31-3.93)/32.301
=0.07

where

Operating Assets(A: Dec. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=24.804 - 18.494
=6.31

Operating Liabilities(A: Dec. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=16.645 - 8.338 - 4.377
=3.93

SymBio Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Dec. 2025 )
=(Operating Assets (Q: Dec. 2025 )-Operating Liabilities (Q: Dec. 2025 ))/Total Assets (Q: Sep. 2025 )
=(6.31-3.93)/30.975
=0.08

where

Operating Assets(Q: Dec. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=24.804 - 18.494
=6.31

Operating Liabilities(Q: Dec. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=16.645 - 8.338 - 4.377
=3.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of 0.08 mean?
SymBio Pharmaceuticals (SYMQY) has a Scaled Net Operating Assets of 0.08 as of Dec. 2025. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on SymBio Pharmaceuticals and its competitors.
Is SymBio Pharmaceuticals' Scaled Net Operating Assets too high?
SymBio Pharmaceuticals' current Scaled Net Operating Assets is 0.08. Overall, SymBio Pharmaceuticals has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does SymBio Pharmaceuticals' Scaled Net Operating Assets compare to ZTS and UTHR?
SymBio Pharmaceuticals' Scaled Net Operating Assets of 0.08 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Drug Manufacturers company?
A good Scaled Net Operating Assets depends on the Drug Manufacturers industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on SymBio Pharmaceuticals and its competitors. SymBio Pharmaceuticals's current Scaled Net Operating Assets is 0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SymBio Pharmaceuticals stock overvalued right now?
SymBio Pharmaceuticals (SYMQY) has a current Scaled Net Operating Assets of 0.08. The stock's GF Value™ is $0.44, compared to a current price of $0.56 — trading 26.8% above its estimated fair value. The current Scaled Net Operating Assets is 0.08. SymBio Pharmaceuticals' overall GF Score™ is 35/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For SymBio Pharmaceuticals (SYMQY), the current Scaled Net Operating Assets is 0.08 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SymBio Pharmaceuticals (SYMQY) Overvalued in 2026?

Based on GuruFocus' analysis, SymBio Pharmaceuticals stock appears to be overvalued. The current stock price of $0.56 is trading 26.8% above its estimated GF Value™ of $0.44.

Key valuation signals for SYMQY:

  • Scaled Net Operating Assets: 0.08
  • GF Value™: $0.44 vs. price of $0.56 (26.8% above fair value)
  • GF Score™: 35/100 with 6 warning signs

No single metric tells the full story. See the SYMQY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SymBio Pharmaceuticals Business Description

Other Exchanges 4582:Japan
Address 1-28 Toranomon 4-chome, 7th Floor, Toranomon Towers Office, Minato-ku, Tokyo, JPN, 105-0001
SymBio Pharmaceuticals Ltd is a biopharmaceutical company engaged in development of new drugs with a primary focus on the treatment of rare diseases, mainly in the areas of oncology, hematology and multiple viral infections, and conduct integrated business activities that encompass search for new drug candidates, development, manufacturing, and sales.
35GF Score

Get the complete analysis for SYMQY

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.56
Price
$0.44
GF Value